tbuckley/cabot-search huggingface dataset:
New evidence about the benefits of PCI with regard to mortality
Authors: M. J. Farebrother
Journal: BMJ (2014)

Having had two stents inserted into a 3.5 cm, angled, and heavily calcified 80% stenosis of my right anterior descending coronary artery at the end of July this year, this subject is close to my heart.

My symptoms were not severe but I had some exertional breathlessness and more recently chest tightness on exertion, probably angina. The cardiologist offered percutaneous coronary intervention (PCI) and said that it …
A6.07 Tissue- and cell-specific transcriptomes indicate systemic nature of ra and revealed combinations of protein biomarkers relevant for disease characterisation in serum
Authors: B Smiljanovic, B Stuhlmüller, T Sörensen, M Bonin, S Pade, B Backhaus, W Maslinski, GR Burmester, A Radbruch, A Grützkau, T Häupl
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background and objectives</h3> Clinical signs and symptoms, radiographic changes and routine laboratory tests have indispensable roles in diagnosis of rheumatoid arthritis (RA). Nevertheless, a high degree of heterogeneity between RA patients and increasing options of treatment require the identification of objective criteria relevant for diagnosis and therapeutic stratification of patients. This study focused on global approaches in dissecting inflammation in RA including transcriptome analyses of synovial tissue, blood and bone marrow monocytes and proteome analyses of selected molecules in serum from long-lasting and early RA. <h3>Materials and methods</h3> Gene-expression profiling of synovial tissues, blood and bone marrow monocytes of RA and osteoarthritis (OA) patients were performed by Affymetrix microarrays. Based on transcriptome data, 28 molecules were selected for protein analyses by ELISA and multiplex immunoassays in sera from patients with long-lasting RA (n = 17) and OA (n = 16), early RA (n = 10) and healthy donors (n = 14). <h3>Results</h3> Transcriptome analyses of synovial tissues from RA and OA patients showed the most prominent differences between these two diseases and identified more than 1000 differentially expressed genes. More subtle differences were disclosed by gene-expression profiling of blood and bone marrow monocytes from RA and OA with 300 and 150 differentially expressed genes, respectively. From RA tissue- and cell-specific transcriptomes 28 genes were selected for protein analyses in serum from RA and OA patients including: chemokines (CXCL13, CCL18), adhesion molecules (VCAM1, ICAM1, E- and P-Selectins), enzymes (MMP3, A1AT), alarmins (S100P and S1008/9) and the soluble form of cell surface molecules (CD14, CD163). Out of 28 markers only 16 reached statistical significance to discriminate long-lasting RA from OA. A combination of 5 markers was able to correctly classify long-lasting RA. However, the same combination of markers identified only one-third of early RA patients. <h3>Conclusions</h3> Tissue- and cell-specific transcriptomes demonstrated the systemic nature of RA. Proteome analyses of serum from long-lasting RA patients confirmed transcriptome data and showed that molecular patterns determined by the combination of inflammatory and cell-specific markers are required for disease stratification. In early RA transcriptome data outperformed proteome data suggesting that focus on transcriptional alterations is more sensitive approach for disease management of early RA.
Health and social services to work more closely in England
Authors: J. Warden
Journal: BMJ (1998)

Divisions between health and social care will be bridged under proposals issued by the government last week in a consultation document describing options for joint working between health and social services in England.

Legislation will enable pooled budgets and integrated services to be established across organisational boundaries, with the emerging primary care trusts seen as being key agencies to coordinate health and social care.

Ministers say that the aim is to demolish the “Berlin wall” …
The Icatibant Outcome Survey: More Than 1500 Icatibant-Treated Attacks in Patients with Type I or II Hereditary Angioedema
Authors: Marcus Maurer, Teresa Caballero, Werner Aberer, Andrea Zanichelli, Laurence Bouillet, Vincent Fabien, Hilary Longhurst
Journal: Journal of Allergy and Clinical Immunology (2015)
Roentgenologic Examination in Patients with Bleeding from the Gastrointestinal Tract
Authors: Richard Schatzki
Journal: New England Journal of Medicine (1946)

MASSIVE hemorrhage from the gastrointestinal tract, particularly hematemesis, is one of the dramatic events in medicine that deeply impress both patient and physician. The question that presents itself urgently to both is, What is the cause of the bleeding? At times the history may give a clue to the diagnosis, whereas at others the bleeding takes place without any preceding symptoms or signs. In rare cases a blood dyscrasia, usually easily recognized, has prompted the hemorrhage, but the answer to the question usually depends on the demonstration of an anatomic lesion.The roentgenologist is burdened with the responsibility of finding . . .
The Local Efficacy of I-131 for F-18 FDG PET Positive Lesions in Patients With Recurrent or Metastatic Thyroid Carcinomas
Authors: Kotaro Yoshio, Shuhei Sato, Yoshihiro Okumura, Kuniaki Katsui, Mitsuhiro Takemoto, Etsuji Suzuki, Norihisa Katayama, Mitsumasa Kaji, Susumu Kanazawa
Journal: Clinical Nuclear Medicine (2011)

The aim of this study was to evaluate the local efficacy of I-131 for F-18 fluorodeoxyglucose positron emission tomography (FDG PET)-positive lesions.Whole-body FDG PET/CT was performed on 37 patients (55 cases: 16 men, 21 women; age range: 24-82 years; mean age ± standard deviation: 60.5 ± 16.0 years) with differentiated thyroid cancer after total thyroidectomy. The metastatic or recurrent lesions were divided into 5 categories: primary tumor bed, lymph node, lung, bone, and other. The well-defined lesions were measured on CT, and the sizes were compared before and after radioactive iodine therapy.The analysis was performed on 37 patients with 44 lesions (lymph node:24, lung:16, bone:4). Sixteen lesions (70%) were increased and 7 (30%) showed no change or reduction when there was positive accumulation on FDG PET/CT and negative accumulation on I-131 (F(+)I(-)) group. In the positive accumulation for both FDG PET/CT and I-131 (F(+)I(+)) group, 5 lesions (63%) were increased and 3 (37%) showed no change or reduction. There was no significant difference for the tendency to increase in size between the F(+)I(-) and the F(+)I(+) groups.Lesions which show positive accumulations on FDG PET/CT have a greater tendency to increase in size. FDG-avid lesions are resistant to radioactive iodine therapy with or without I-131 uptake.
THU0239 Cardiovascular risk factors in adults with polymyositis and dermatomyositis – a multicenter study
Authors: L.C. Diederichsen, A.C. Diederichsen, J.A. Simonsen, P. Junker, K. Søndergaard, I.E. Lundberg, N. Tvede, A.F. Christensen, L. Dreyer, L. Ejstrup, S. Jacobsen
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> CVD is a major cause of death among patients with PM or DM. Still, data on prevalence and types of cardiovascular involvement and corresponding risk factors are limited and no systematic studies of subclinical coronary atherosclerosis have been performed in adults with PM or DM. <h3>Objectives</h3> Our purpose was to determine the distribution of traditional CVD risk factors and to assess CAC in adults with PM or DM. <h3>Methods</h3> In a cross-sectional, observational study of 76 prevalent patients with PM (n=51) or DM (n=25) clinical and immunological variables and the following traditional CVD risk factors were assessed: age, sex, CVD family history, smoking (current, former or never), body mass index (BMI), blood pressure (BP), total cholesterol (TC), LDL cholesterol (LDL-C), and mean blood glucose (mBG) calculated from HbA1c. Further, CAC were quantified by means of non-contrast enhanced cardiac CT scan and reported as a CAC score with the following ranges; no calcifications (CAC score =0 U); low CAC score (1-399 U); or high CAC score (≥400 U). High CAC score is consistent with severe coronary atherosclerosis. <h3>Results</h3> The mean age of the patients was 60 years (range 33-85) and 65% were women. A CVD family history was reported in 20% of the patients and 25% were current smokers; 28% were former smokers. Overweight (25≤BMI&lt;30) was observed in 23 (30%) whereas 33 (43%) were obese (BMI&gt;30). High systolic blood pressure (&gt;140 mmHg) was observed in 35 (47%); 54 (74%) had high TC (&gt;4.95 mmol/L), and 41 (59%) high LDL-C as well. mBG was increased (&gt;6.95 mmol/L) in 16 (21%) patients. A CAC score &gt;0 was noticed in 46 (61%) of whom 15 (20%) had a high score. <h3>Conclusions</h3> We report that a significant proportion of patients with PM or DM have a high burden of CVD risk factors and evidence of clinically significant calcium deposits in their coronary arteries. Several chronic inflammatory rheumatic diseases are associated with accelerated atherosclerosis, which may also apply to PM/DM. To what extent the increased CAC score is related to disease severity, the burden of CVD risk factors, prednisolone treatment or combinations hereof cannot be decided from this cross-sectional study. However, these preliminary data indicate that a prospective assessment of the CV system is warranted in PM and DM. <h3>Disclosure of Interest</h3> None Declared
AB0129 Mechanisms of t cell recruitment in lupus nephritis
Authors: J. R. Klocke, C. von Spee-Mayer, P. Enghard, G. Riemekasten
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Local T cell infiltration is considered to play an important role in the pathogenesis of lupus nephritis (LN), one of the major complications of Systemic Lupus Erythematosus (SLE). The renal inflitrating cells can also be found in high numbers in the urine of patients with active LN, however little is known about how these cells are recruited into the inflamed kidney. <h3>Objectives</h3> Identifying how conventional CD4+ and CD8+ T cells and regulatory T cells (Treg) are recruited into the inflamed kidney in LN. <h3>Methods</h3> Serum and urine samples of 98 SLE patients were analyzed for 17 chemokines using multiplex assays. Based on the assay's results a group of 8 corresponding chemokine receptors (CCR1 - 6, CXCR3 and CXCR6) was chosen, whose frequencies on urinary T cells were subsequently determined in 7 patients with acute LN by flowcytometry. <h3>Results</h3> 10 chemokines* were significantly elevated in the urine of patients with active LN when compared to the control group. The other 7 chemokines° showed no significant differences between the groups. CCR5 and CXCR3 were the most prominent receptors on both urinary CD4+ and CD8+ T cells, although CD4+ T cells also expressed high amounts of CCR4 and CCR6. The chemokine receptor expression on CD4+FoxP3+CD127- Treg differed from conventional CD4+ T cells as well. Treg expressed significantly more CCR4 and significantly less CXCR6. *: CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CXCL9, CXCL10 and CXCL16 °: CCL1, CCL17, CCL20, CCL22, CXCL1, CXCL5 and CXCL11 <h3>Conclusions</h3> CCR5 and CXCR3 are the primary receptors in the mechanism of recruiting all T cells into the inflamed kidney. Key chemokines for T cell attraction are CCL4, CCL5 and CCL8 as well as CXCL9 and CXCL10. However, at least for CD4+ T cells, there are secondary pathways of recruitment involving CCR4 and CCR6. Also, Treg recruitment seems to rely more on CCR4 than that of conventional CD4+ T cells. <h3>Disclosure of Interest</h3> None Declared
Endoscopic resection of early esophageal neoplasia in patients with esophageal varices: how to succeed while preventing the bleed
Authors: Hannah Künzli, Bas Weusten
Journal: Endoscopy (2014)

Endoscopic resection is an accepted treatment modality for early esophageal neoplasia [1] [2] [3]. In patients with esophageal varices, however, endotherapy is contraindicated, although those patients are also precluded from esophagectomy.
Bacteremia Due to Gram-Negative Rods
Authors: J. I. Maiztegui, J. Z. Biegeleisen, W. B. Cherry, E. H. Kass
Journal: New England Journal of Medicine (1965)

THERE is increasing recognition of the changing ecology of infectious diseases,1 2 3 particularly within the hospital environment. Autochthonous bacteria,4 , 5 especially the gram-negative enteric flora,3 have emerged as the etiologic agents in increasing numbers of infections.Many factors undoubtedly account for the increasing prominence of autogenous bacteria as pathogens. The prolonged life of the general population leads to a higher proportion of persons with degenerative and chronic diseases. The increasing use of potent drugs, such as antimetabolites and steroid hormones, may alter the host resistance to an indigenous flora. The widespread use of antibiotics may lead to the emergence in hospitals, and . . .
Abstract 5247: Expression and functional role of CCR9 in lung cancer
Authors: Rajesh Singh, James W. Lillard, William E. Grizzle, Shailesh Singh
Journal: Cancer Research (2011)

Abstract Lung cancer is leading cause of cancer related deaths worldwide in both men and women. Metastasis is responsible for most lung cancer related deaths; therefore, a better understanding of the metastatic processes and therapies designed to prevent the spread of cancer cells are greatly needed. The specific mechanisms that promote metastases have not been fully elucidated. Among all known chemokine receptors involved in cancer progression, most cancer cells including lung cancer express CXCR4. Furthermore, involvement of CXCR4 and CCR7 in breast cancer and CXCR4, CCR9 and CX3CR1 in prostate cancer progression further indicates that multiple chemokine receptors are involved in dictating the multi-step process of metastasis. For the first time, we show that lung cancer cells and tissue form Non Small Cell Lung Carcinoma (NSCLC) express CCR9, which is the receptor for CCL25. CCR9 was highly expressed by NSCLC cell lines as compared to Small Cell Lung Carcinoma (SCLC) cell lines at mRNA and protein levels. Furthermore, we have shown that CCR9-CCL25 interaction plays a crucial role in lung cancer cell migration. It addition to these, serum levels of CCL25 was significantly elevated in lung cancer patents compared to normal healthy donor. The mechanism underlying these clinically and biologically important finding need to be further explored. Increased serum CCL25 in lung cancer patients with metastatic disease required further validation as a potential therapeutic target and/or diagnostic marker for lung cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5247. doi:10.1158/1538-7445.AM2011-5247
Case 11-1992
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, D.C. Johnson, E.J. Mark
Journal: New England Journal of Medicine (1992)

Presentation of CaseA 77-year-old man was admitted to the hospital because of progressive exertional dyspnea and worsening cough.There was a history of 35 years of smoking two to three packs of cigarettes daily, a habit that he discontinued 20 years before admission. Thirteen months before entry an x-ray film of the chest (Fig. 1) showed small lung volumes and diffuse linear opacities throughout both lungs that were more prominent at the bases; the heart and mediastinum appeared normal. A CT scan of the thorax (Fig. 2), obtained 10 months before entry during an episode of pneumococcal pneumonia, revealed . . .
EUS-guided Treatment of Pancreas Cystic Tumors: Ethanol Lavage followed by Paclitaxol Injection
Authors: DW Seo
Journal: Endoscopy (2006)

Background: EUS-guided ethanol lavage has been tried to ablate cystic lesions of the pancreas and proven to be feasible and safe modality. However, there seems to be a significant number of cystic lesions unresponsive to this type of treatment. This study was conducted to test the feasibility, safety and efficacy of EUS-guided ethanol lavage and paclitaxol injection for the treatment of pancreatic cystic tumors.
Author’s reply: Measles on a cruise ship - links with the outbreak in the Philippines
Authors: S Lanini, M R Capobianchi, T Derrough, E Severi, L Vellucci, M G Pompa
Journal: Eurosurveillance (2014)

Preview this article: Author’s reply: Measles on a cruise ship - links with the outbreak in the Philippines, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/19/15/art20773-en-1.gif
Abstract 737: Hypofractionated stereotactic radiotherapy to surgical cavity after resection for brain metastasis
Authors: Hsiang-Hsuan M. Yu, Ya-Yu Tsai
Journal: Cancer Research (2012)

Abstract Recurrence at resection cavity after resection for brain metastasis is high; whole brain radiotherapy (WBRT) decreases this risk but may cause neurocognitive complication. Post-operative radiosurgery to resection cavity is a new technique to decrease recurrence and spare patients from WBRT, but single high-dose fraction may potentially increase radiation-induced necrosis. Hypofractionated stereotactic radiotherapy (SRT) delivers higher radiobiological dose which may potentially provide higher local tumor control, and fractionation may lower risk of radiation-induced injury. To investigate the efficacy of post-operative hypofractionated SRT after resection of brain metastasis, we retrospectively analyzed 52 consecutive patients with brain metastasis from solid tumors who underwent surgical resection followed by SRT to the resection cavity for at least one metastasis from April 2008 to March 2011. A total of 25 to 30 Gy in 5 daily fractions over 1-week period was prescribed to the resection cavity with a margin of 2 mm expansion (median dose 28.5 Gy) between 2 to 4 weeks post-operatively. Synchronous oligometastasis, if present, was treated with radiosurgery. No patients received upfront WBRT. All patients were followed up for at least 6 months. Follow-up was assessed using clinical evaluation and MR imaging every 2 to 3 months. The radiographic end point was local tumor control at resection cavity. Preliminary analyses showed the actuarial local control rate of 86% at 12 months at the resection site. For those with synchronous brain metastasis, the rates of local control at resection cavity and oligometastases were not statistically significantly different (p=0.4). Approximately 30% of the patients developed distant brain recurrence during follow-up, and 70% of these patients received salvage radiosurgery while the rest received WBRT. None of the patient developed radiation-induced injury at the resection site. Multivariate analysis showed that number of metastasis was associated with higher rate of distant brain recurrence. Hypofractionated SRT appears to be safe and effective in preventing recurrence at resection cavity following surgical resection of brain metastasis and may spare many patients from WBRT and its adverse effects. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 737. doi:1538-7445.AM2012-737
Phase II trial of postoperative concurrent chemoradiotherapy (CCRT) for poor-prognosis cancer of the esophagus and gastroesophageal junction (GEJ)
Authors: D. J. Adelstein, T. W. Rice, L. A. Rybicki, J. P. Saxton, G. M. Videtic, S. C. Murthy, D. P. Mason, C. P. Rodriguez, D. I. Ives
Journal: Journal of Clinical Oncology (2008)

15519 Background: CCRT is effective pre-operative and definitive treatment for patients (pts) with esophageal or GEJ cancer. This phase II trial was conducted to assess the benefit of post-operative CCRT in poor-prognosis pts after primary surgical resection. Methods: Resected pts with a pathologic stage of T3, N1 or M1a have a poor prognosis after surgery alone and were eligible for this trial. CCRT was begun between 6–10 weeks after surgery and consisted of radiotherapy (1.8 Gy/day (d) to a dose of 50.4–54 Gy), concurrent with two cycles of fluorouracil (1000 mg/m2/d) and cisplatin, (20 mg/m2/d); both given as 4-d continuous intravenous infusions during weeks 1 and 4 of the radiation. Primary end points were overall survival (OS) and freedom from recurrence (FFR). Results: Between 1994 and 2005, 50 pts were enrolled. The median age was 59 (range 33–76) years; 43 pts (86%) were male, and 48 (96%) were Caucasian. Histology was adenocarcinoma (ACA) in 43 pts (86%), and squamous cell carcinoma (SCC) in 7 (14%); and tumor originated in mid-esophagus in 4 (8%), distal esophagus 10 (20%) and GEJ in 36 (72%). The surgical procedure was a transthoracic esophagogastrectomy in 37 pts (74%), total gastrectomy in 8 (16%) and transhiatal esophagectomy in 5 (10%). Pathologic stage was T3N0M0 in 7 pts (14%), T1–4N1M0 in 40 (80%) and M1a in 3 (6%); 9 pts (18%) had positive margins. Postoperative CCRT was well tolerated with grade 3–4 nausea/vomiting in 4 pts (8%), mucositis/dysphagia in 6 (12%), and neutropenia < 1000/mm3 in 16 (32%) requiring hospitalization for fever in 4 (8%). There were no toxic deaths. With a median follow up of 63 (range 24–109) months, the Kaplan-Meier 5-year projected OS is 41%, FFR 42%, locoregional control 85% and distant metastatic disease control 47%. FFR was better in pts with SCC vs. ACA (86% vs. 34%, P=0.038). When comparing pts with T3N0, N1M0, and M1a disease, both OS (67% vs. 40% vs. 0%, P= 0.007) and FFR (80% vs. 35% vs. 0%, P=0.027), were better in pts with earlier pathologic stage. Conclusions: This schedule of postoperative CCRT is well tolerated in patients with poor-prognosis esophageal and GEJ cancer after surgery. Outcomes are better than historical results after surgery alone and justify further investigation of this approach. No significant financial relationships to disclose.
A Road Map for the Cancer Information Highway
Authors: K. Nagy
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article A Road Map for the Cancer Information Highway Get access Kate Nagy Kate Nagy Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 15, 3 August 1994, Page 1117, https://doi.org/10.1093/jnci/86.15.1117 Published: 03 August 1994